Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.
Identifieur interne : 000630 ( Main/Exploration ); précédent : 000629; suivant : 000631Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.
Auteurs : Mark Loeb [Canada] ; Margaret L. Russell ; Lorraine Moss ; Kevin Fonseca ; Julie Fox ; David J D. Earn ; Fred Aoki ; Gregory Horsman ; Paul Van Caeseele ; Khami Chokani ; Mark Vooght ; Lorne Babiuk ; Richard Webby ; Stephen D. WalterSource :
- JAMA [ 1538-3598 ] ; 2010.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Canada (épidémiologie), Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Femelle, Grippe humaine (), Grippe humaine (transmission), Grippe humaine (épidémiologie), Humains, Jeune adulte, Mâle, Méthode en double aveugle, Population rurale, RT-PCR, Religion, Sujet âgé, Vaccins anti-hépatite A (administration et posologie), Vaccins antigrippaux (administration et posologie), Virus de la grippe A (génétique), Virus de la grippe A (immunologie), Virus influenza B (génétique), Virus influenza B (immunologie).
- MESH :
- administration et posologie : Vaccins anti-hépatite A, Vaccins antigrippaux.
- génétique : Virus de la grippe A, Virus influenza B.
- immunologie : Virus de la grippe A, Virus influenza B.
- épidémiologie : Canada, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Population rurale, RT-PCR, Religion, Sujet âgé.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adolescent, Adult, Age Factors, Aged, Canada (epidemiology), Child, Child, Preschool, Double-Blind Method, Female, Hepatitis A Vaccines (administration & dosage), Humans, Influenza A virus (genetics), Influenza A virus (immunology), Influenza B virus (genetics), Influenza B virus (immunology), Influenza Vaccines (administration & dosage), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (transmission), Male, Middle Aged, Religion, Reverse Transcriptase Polymerase Chain Reaction, Rural Population, Young Adult.
- MESH :
- chemical , administration & dosage : Hepatitis A Vaccines, Influenza Vaccines.
- geographic , epidemiology : Canada.
- epidemiology : Influenza, Human.
- genetics : Influenza A virus, Influenza B virus.
- immunology : Influenza A virus, Influenza B virus.
- prevention & control : Influenza, Human.
- transmission : Influenza, Human.
- Adolescent, Adult, Age Factors, Aged, Child, Child, Preschool, Double-Blind Method, Female, Humans, Male, Middle Aged, Religion, Reverse Transcriptase Polymerase Chain Reaction, Rural Population, Young Adult.
Abstract
CONTEXT
Children and adolescents appear to play an important role in the transmission of influenza. Selectively vaccinating youngsters against influenza may interrupt virus transmission and protect those not immunized.
OBJECTIVE
To assess whether vaccinating children and adolescents with inactivated influenza vaccine could prevent influenza in other community members.
DESIGN, SETTING, AND PARTICIPANTS
A cluster randomized trial involving 947 Canadian children and adolescents aged 36 months to 15 years who received study vaccine and 2326 community members who did not receive the study vaccine in 49 Hutterite colonies in Alberta, Saskatchewan, and Manitoba. Follow-up began December 28, 2008, and ended June 23, 2009.
INTERVENTION
Children were randomly assigned according to community and in a blinded manner to receive standard dosing of either inactivated trivalent influenza vaccine or hepatitis A vaccine, which was used as a control.
MAIN OUTCOME MEASURES
Confirmed influenza A and B infection using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay and by measuring serum hemagglutination inhibition titers.
RESULTS
The mean rate of study vaccine coverage among eligible participants was 83% (range, 53%-100%) for the influenza vaccine colonies and 79% (range, 50%-100%) for the hepatitis A vaccine colonies. Among nonrecipients, 39 of 1271 (3.1%) in the influenza vaccine colonies and 80 of 1055 (7.6%) in the hepatitis A vaccine colonies had influenza illness confirmed by RT-PCR, for a protective effectiveness of 61% (95% confidence interval [CI], 8%-83%; P = .03). Among all study participants (those who were and those who were not vaccinated), 80 of 1773 (4.5%) in the influenza vaccine colonies and 159 of 1500 (10.6%) in the hepatitis A vaccine colonies had influenza illness confirmed by RT-PCR for an overall protective effectiveness of 59% (95% CI, 5%-82%; P = .04). No serious vaccine adverse events were observed.
CONCLUSION
Immunizing children and adolescents with inactivated influenza vaccine significantly protected unimmunized residents of rural communities against influenza.
TRIAL REGISTRATION
clinicaltrials.gov Identifier: NCT00877396.
DOI: 10.1001/jama.2010.250
PubMed: 20215608
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.</title><author><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Molecular Medicine, McMaster University, 1200 Main St W, Hamilton, ON, L8N 3Z5 Canada. loebm@mcmaster.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Russell, Margaret L" sort="Russell, Margaret L" uniqKey="Russell M" first="Margaret L" last="Russell">Margaret L. Russell</name></author><author><name sortKey="Moss, Lorraine" sort="Moss, Lorraine" uniqKey="Moss L" first="Lorraine" last="Moss">Lorraine Moss</name></author><author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name></author><author><name sortKey="Fox, Julie" sort="Fox, Julie" uniqKey="Fox J" first="Julie" last="Fox">Julie Fox</name></author><author><name sortKey="Earn, David J D" sort="Earn, David J D" uniqKey="Earn D" first="David J D" last="Earn">David J D. Earn</name></author><author><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name></author><author><name sortKey="Horsman, Gregory" sort="Horsman, Gregory" uniqKey="Horsman G" first="Gregory" last="Horsman">Gregory Horsman</name></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name></author><author><name sortKey="Chokani, Khami" sort="Chokani, Khami" uniqKey="Chokani K" first="Khami" last="Chokani">Khami Chokani</name></author><author><name sortKey="Vooght, Mark" sort="Vooght, Mark" uniqKey="Vooght M" first="Mark" last="Vooght">Mark Vooght</name></author><author><name sortKey="Babiuk, Lorne" sort="Babiuk, Lorne" uniqKey="Babiuk L" first="Lorne" last="Babiuk">Lorne Babiuk</name></author><author><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name></author><author><name sortKey="Walter, Stephen D" sort="Walter, Stephen D" uniqKey="Walter S" first="Stephen D" last="Walter">Stephen D. Walter</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20215608</idno><idno type="pmid">20215608</idno><idno type="doi">10.1001/jama.2010.250</idno><idno type="wicri:Area/Main/Corpus">000670</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000670</idno><idno type="wicri:Area/Main/Curation">000670</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000670</idno><idno type="wicri:Area/Main/Exploration">000670</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.</title><author><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Molecular Medicine, McMaster University, 1200 Main St W, Hamilton, ON, L8N 3Z5 Canada. loebm@mcmaster.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Russell, Margaret L" sort="Russell, Margaret L" uniqKey="Russell M" first="Margaret L" last="Russell">Margaret L. Russell</name></author><author><name sortKey="Moss, Lorraine" sort="Moss, Lorraine" uniqKey="Moss L" first="Lorraine" last="Moss">Lorraine Moss</name></author><author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name></author><author><name sortKey="Fox, Julie" sort="Fox, Julie" uniqKey="Fox J" first="Julie" last="Fox">Julie Fox</name></author><author><name sortKey="Earn, David J D" sort="Earn, David J D" uniqKey="Earn D" first="David J D" last="Earn">David J D. Earn</name></author><author><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name></author><author><name sortKey="Horsman, Gregory" sort="Horsman, Gregory" uniqKey="Horsman G" first="Gregory" last="Horsman">Gregory Horsman</name></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name></author><author><name sortKey="Chokani, Khami" sort="Chokani, Khami" uniqKey="Chokani K" first="Khami" last="Chokani">Khami Chokani</name></author><author><name sortKey="Vooght, Mark" sort="Vooght, Mark" uniqKey="Vooght M" first="Mark" last="Vooght">Mark Vooght</name></author><author><name sortKey="Babiuk, Lorne" sort="Babiuk, Lorne" uniqKey="Babiuk L" first="Lorne" last="Babiuk">Lorne Babiuk</name></author><author><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name></author><author><name sortKey="Walter, Stephen D" sort="Walter, Stephen D" uniqKey="Walter S" first="Stephen D" last="Walter">Stephen D. Walter</name></author></analytic><series><title level="j">JAMA</title><idno type="eISSN">1538-3598</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Canada (epidemiology)</term><term>Child</term><term>Child, Preschool</term><term>Double-Blind Method</term><term>Female</term><term>Hepatitis A Vaccines (administration & dosage)</term><term>Humans</term><term>Influenza A virus (genetics)</term><term>Influenza A virus (immunology)</term><term>Influenza B virus (genetics)</term><term>Influenza B virus (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (transmission)</term><term>Male</term><term>Middle Aged</term><term>Religion</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>Rural Population</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada (épidémiologie)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (transmission)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Population rurale</term><term>RT-PCR</term><term>Religion</term><term>Sujet âgé</term><term>Vaccins anti-hépatite A (administration et posologie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Virus de la grippe A (génétique)</term><term>Virus de la grippe A (immunologie)</term><term>Virus influenza B (génétique)</term><term>Virus influenza B (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hepatitis A Vaccines</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins anti-hépatite A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Child</term><term>Child, Preschool</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Religion</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>Rural Population</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Population rurale</term><term>RT-PCR</term><term>Religion</term><term>Sujet âgé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>CONTEXT</b></p><p>Children and adolescents appear to play an important role in the transmission of influenza. Selectively vaccinating youngsters against influenza may interrupt virus transmission and protect those not immunized.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To assess whether vaccinating children and adolescents with inactivated influenza vaccine could prevent influenza in other community members.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN, SETTING, AND PARTICIPANTS</b></p><p>A cluster randomized trial involving 947 Canadian children and adolescents aged 36 months to 15 years who received study vaccine and 2326 community members who did not receive the study vaccine in 49 Hutterite colonies in Alberta, Saskatchewan, and Manitoba. Follow-up began December 28, 2008, and ended June 23, 2009.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTION</b></p><p>Children were randomly assigned according to community and in a blinded manner to receive standard dosing of either inactivated trivalent influenza vaccine or hepatitis A vaccine, which was used as a control.</p></div><div type="abstract" xml:lang="en"><p><b>MAIN OUTCOME MEASURES</b></p><p>Confirmed influenza A and B infection using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay and by measuring serum hemagglutination inhibition titers.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The mean rate of study vaccine coverage among eligible participants was 83% (range, 53%-100%) for the influenza vaccine colonies and 79% (range, 50%-100%) for the hepatitis A vaccine colonies. Among nonrecipients, 39 of 1271 (3.1%) in the influenza vaccine colonies and 80 of 1055 (7.6%) in the hepatitis A vaccine colonies had influenza illness confirmed by RT-PCR, for a protective effectiveness of 61% (95% confidence interval [CI], 8%-83%; P = .03). Among all study participants (those who were and those who were not vaccinated), 80 of 1773 (4.5%) in the influenza vaccine colonies and 159 of 1500 (10.6%) in the hepatitis A vaccine colonies had influenza illness confirmed by RT-PCR for an overall protective effectiveness of 59% (95% CI, 5%-82%; P = .04). No serious vaccine adverse events were observed.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Immunizing children and adolescents with inactivated influenza vaccine significantly protected unimmunized residents of rural communities against influenza.</p></div><div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b></p><p>clinicaltrials.gov Identifier: NCT00877396.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20215608</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>303</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.</ArticleTitle><Pagination><MedlinePgn>943-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2010.250</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Children and adolescents appear to play an important role in the transmission of influenza. Selectively vaccinating youngsters against influenza may interrupt virus transmission and protect those not immunized.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether vaccinating children and adolescents with inactivated influenza vaccine could prevent influenza in other community members.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A cluster randomized trial involving 947 Canadian children and adolescents aged 36 months to 15 years who received study vaccine and 2326 community members who did not receive the study vaccine in 49 Hutterite colonies in Alberta, Saskatchewan, and Manitoba. Follow-up began December 28, 2008, and ended June 23, 2009.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Children were randomly assigned according to community and in a blinded manner to receive standard dosing of either inactivated trivalent influenza vaccine or hepatitis A vaccine, which was used as a control.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Confirmed influenza A and B infection using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay and by measuring serum hemagglutination inhibition titers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean rate of study vaccine coverage among eligible participants was 83% (range, 53%-100%) for the influenza vaccine colonies and 79% (range, 50%-100%) for the hepatitis A vaccine colonies. Among nonrecipients, 39 of 1271 (3.1%) in the influenza vaccine colonies and 80 of 1055 (7.6%) in the hepatitis A vaccine colonies had influenza illness confirmed by RT-PCR, for a protective effectiveness of 61% (95% confidence interval [CI], 8%-83%; P = .03). Among all study participants (those who were and those who were not vaccinated), 80 of 1773 (4.5%) in the influenza vaccine colonies and 159 of 1500 (10.6%) in the hepatitis A vaccine colonies had influenza illness confirmed by RT-PCR for an overall protective effectiveness of 59% (95% CI, 5%-82%; P = .04). No serious vaccine adverse events were observed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Immunizing children and adolescents with inactivated influenza vaccine significantly protected unimmunized residents of rural communities against influenza.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00877396.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loeb</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Molecular Medicine, McMaster University, 1200 Main St W, Hamilton, ON, L8N 3Z5 Canada. loebm@mcmaster.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Margaret L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Lorraine</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fonseca</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Earn</LastName><ForeName>David J D</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Horsman</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Van Caeseele</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chokani</LastName><ForeName>Khami</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vooght</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Babiuk</LastName><ForeName>Lorne</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Webby</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00877396</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022362">Hepatitis A Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2010 Jun 16;303(23):2355-6; author reply 2356</RefSource><PMID Version="1">20551404</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2010 Jul 20;153(2):JC1-10</RefSource><PMID Version="1">20643976</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022362" MajorTopicYN="N">Hepatitis A Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012067" MajorTopicYN="N">Religion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012424" MajorTopicYN="N">Rural Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20215608</ArticleId><ArticleId IdType="pii">303/10/943</ArticleId><ArticleId IdType="doi">10.1001/jama.2010.250</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name><name sortKey="Babiuk, Lorne" sort="Babiuk, Lorne" uniqKey="Babiuk L" first="Lorne" last="Babiuk">Lorne Babiuk</name><name sortKey="Chokani, Khami" sort="Chokani, Khami" uniqKey="Chokani K" first="Khami" last="Chokani">Khami Chokani</name><name sortKey="Earn, David J D" sort="Earn, David J D" uniqKey="Earn D" first="David J D" last="Earn">David J D. Earn</name><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name><name sortKey="Fox, Julie" sort="Fox, Julie" uniqKey="Fox J" first="Julie" last="Fox">Julie Fox</name><name sortKey="Horsman, Gregory" sort="Horsman, Gregory" uniqKey="Horsman G" first="Gregory" last="Horsman">Gregory Horsman</name><name sortKey="Moss, Lorraine" sort="Moss, Lorraine" uniqKey="Moss L" first="Lorraine" last="Moss">Lorraine Moss</name><name sortKey="Russell, Margaret L" sort="Russell, Margaret L" uniqKey="Russell M" first="Margaret L" last="Russell">Margaret L. Russell</name><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><name sortKey="Vooght, Mark" sort="Vooght, Mark" uniqKey="Vooght M" first="Mark" last="Vooght">Mark Vooght</name><name sortKey="Walter, Stephen D" sort="Walter, Stephen D" uniqKey="Walter S" first="Stephen D" last="Walter">Stephen D. Walter</name><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name></noCountry><country name="Canada"><noRegion><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000630 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000630 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20215608
|texte= Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20215608" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |